People · Operator
Named in public records as an officer, director or promoter · active 2009–2014 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Jaguar Health, Inc. | — | Pharmaceuticals | Series C | $151.1M | $58.9M | 2013 |
| Napo Pharmaceuticals Inc | — | Biotechnology | Seed | $10.1M | $6.1M | 2009 |
Charles Thompson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Thompson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven King | 2 | 6 |
| Pravin Chaturvedi | 2 | 4 |
| Lisa Conte | 2 | 3 |
| Anula Jayasuriya | 1 | 5 |
| James J. Bochnowski | 1 | 5 |
| Jonathan Siegel | 1 | 5 |
| Dennis Fenton | 1 | 4 |
| John Kallassy | 1 | 4 |
| Richard Fields | 1 | 4 |
| James Bochnowski | 1 | 4 |
| Joshua Mailman | 1 | 4 |
| Serge Martinod | 1 | 3 |
| Ari Azhir | 1 | 3 |
| Zhi Yang | 1 | 2 |
| Jeffery Johnson | 1 | 2 |
| Jack Van Hulst | 1 | 2 |
| John Micek III | 1 | 2 |
| Gregory Stock | 1 | 2 |
| Carol Lizak | 1 | 2 |
| Jonathan Wolin | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.